Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 63Colorectal Neoplasms 30Biliary Tract Neoplasms 29Cholangiocarcinoma 27Pancreatic Neoplasms 26Liver Neoplasms 18Stomach Neoplasms 13Esophageal Neoplasms 11Carcinoma, Non-Small-Cell Lung 11Breast Neoplasms 10Gallbladder Neoplasms 9Adenocarcinoma Of Esophagus 9Neoplasm Metastasis 8Esophageal Squamous Cell Carcinoma 8Ovarian Neoplasms 7Melanoma 7Squamous Cell Carcinoma of Head and Neck 6Small Cell Lung Carcinoma 6Carcinoma, Renal Cell 6Carcinoma 6Bile Duct Neoplasms 6Triple Negative Breast Neoplasms 5Rectal Neoplasms 5Prostatic Neoplasms 5Colonic Neoplasms 5Uterine Cervical Neoplasms 4Lung Neoplasms 4Diabetes Mellitus, Insulin-Dependent, 12 4Adenocarcinoma 4Neoplasms 3

Interventions

Propranolol 3Portasystemic Shunt, Transjugular Intrahepatic 2tremelimumab 1durvalumab 1Radiofrequency Ablation 1Liver Transplantation 1Hepatectomy 1Diagnostic Imaging 1Carvedilol 1Bevacizumab 16-acetylaminocaproic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypertension, Portal × durvalumab × Gastrointestinal × Clear all
NCT05027425 2026-05-06

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

University of Cincinnati

Phase 2 Terminated
8 enrolled 9 charts
Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular, Hypertension, Portal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡